The global orphan drugs market is predicted to touch USD 2,23,646.51 million at an 11.50% CAGR over the forecast period (2018-2023), in accordance with the latest Market Research Future (MRFR) report. Orphan drugs, simply put, are medicinal drugs that are intended to diagnose, prevent, or treat serious or life-threatening disorders or diseases which are rare. The reason these drugs are called orphan is owing to the fact that they are manufactured in minimal quantities with the pharmaceutical sector having little interest in them.
Get Prime Sample Report at https://www.marketresearchfuture.com/sample_request/2312
Various factors are propelling the orphan drugs market growth. These factors, in accordance with the MRFR report, include the rising emphasis of pharmaceutical companies on orphan drug improvement, rising incidences of rare diseases, and various initiatives undertaken by the government for orphan medicine. Additional factors pushing market growth include improving regulatory framework, growing awareness regarding rare disease, growth in the pharmaceutical and biotechnology sector, and increase in drug development and research and development investment.
On the contrary, poor healthcare systems in middle and low-income countries, lack of specificity, and stringent FDA regulation are factors that may restrict the orphan drugs market growth over the forecast period.
Leading players profiled in the orphan drugs market report include Bristol Meyer Squibb, Pfizer Inc., Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Janssen Global Services LLC, Sanofi, Shire Pharmaceutical, Eli Lilly and Company, Merck KGaA, Takeda Pharmaceutical Company Limited, Biogen, Novartis AG, Celgene Corporation, Mylan, and F. Hoffmann-La Roche AG, among others. Key players have used some strategies to cater to the growing needs of orphan drugs and also strengthen their position in the market. These strategies include research and development, product innovations and launches, mergers and acquisitions, partnerships, collaborations, joint ventures, and many others.
September 2019: Leading pharmaceutical company, Glenmark Pharmaceuticals has recently received the orphan drug designation GBR 1342, its antibody candidate that is under development to treat patients having multiple myeloma and have received prior therapies.
The MRFR report provides a complete segmental analysis of the orphan drugs market report on the basis of therapy class, drug, sale, and drug type.
Based on drug type, the orphan drugs market is segmented into non-biologics and biologics. Of these, the biologics segment will have the largest share in the market over the forecast period.
Based on sale, the orphan drugs market is segmented into prescribed and generics.
Based on drug, the orphan drugs market is segmented into adcetris, spinraza, pomalyst, jakaf, soliris, imbruvica, Keytruda, opdivo, Rituxan, and Revlimid.
Based on therapy class, the orphan drugs market is segmented into respiratory, cardiovascular, endocrine, central nervous systems, blood, and oncology.
By region, the orphan drugs market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will dominate the market over the forecast period. This is chiefly owing to the rising occurrence of rare disorders in the region.
The orphan drugs market in Europe is predicted to have the second-largest share in the market over the forecast period. This is owing to the growing number of pharmaceutical companies that are exporting products within or outside Europe. The majority of the companies in Europe are engaged in R&D of orphan drugs as per the needs of the patients. Moreover, strong clinical pipeline, unmet medical necessities, reimbursement, favorable pricing, and introduction of innovative technologies are also pushing market growth.
The orphan drugs market in the APAC region is predicted to grow at the fastest pace over the forecast period. This is owing to increasing population, growing prevalence of other diseases including respiratory disorders, cardiovascular & lymphatic systems, and endocrinology.
Browse Complete 84 Pages Premium Research Report Enabled with 121 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312
Table of Contents
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.2 Scope of The Study
3.3 Assumptions & Limitations
3.4 Market Structure
List of Tables
TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL ORPHAN DRUGS MARKET FOR BIOLOGICS, BY REGION, 2015–2023 (USD MILLION)
TABLE 5 GLOBAL ORPHAN DRUGS MARKET FOR NON-BIOLOGICS, BY REGION, 2015–2023 (USD MILLION)
TABLE 6 GLOBAL ORPHAN DRUGS MARKET, BY SALE, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL ORPHAN DRUGS MARKET FOR GENERICS, BY REGION, 2015–2023 (USD MILLION)
List of Figures
FIGURE 1 GLOBAL ORPHAN DRUGS MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ORPHAN DRUGS MARKET
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS OF GLOBAL ORPHAN DRUGS MARKET
FIGURE 6 SUPPLY CHAIN: ORPHAN DRUGS MARKET
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312